Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,403 across all filing types
Latest filing 2019-04-01 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
SELUMETINIB GETS BREAKTHROUGH THERAPY DESIGNATION
Regulatory Filings
2019-04-01 English
Selumetinib gets Breakthrough Therapy Designation
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated 01 April 2019. The content is a press release announcing that the FDA granted Breakthrough Therapy Designation (BTD) for a drug (Selumetinib). This type of announcement, which disseminates material, non-financial news to the market via an official channel (RNS, regulated by the FCA), fits best under the general 'Regulatory Filings' category, as it is not a specific financial report (like 10-K, ER, or IR), nor is it a management change (MANG) or dividend notice (DIV). The presence of the RNS header strongly suggests this classification.
2019-04-01 English
RESULTS OF PLACING
Regulatory Filings
2019-03-29 English
Results of Placing
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated March 29, 2019. It explicitly announces the 'successful completion of the placing' of new ordinary shares, detailing the number of shares, the placing price, and the proceeds raised (£2.69 billion). This clearly relates to a capital-raising or financing activity. The document also mentions applications for admission to the Official List and London Stock Exchange, and concludes with contact information typical of a regulatory news service announcement. Since the core subject is the successful completion of a share placement to raise capital, the most appropriate category is 'Capital/Financing Update' (CAP). Although it is distributed via RNS, the specific content overrides the general RNS fallback.
2019-03-29 English
AZ AND DAIICHI SANKYO ENTER COLLABORATION IN NOVEL
Regulatory Filings
2019-03-29 English
Proposed placing of new ordinary shares
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement from AstraZeneca PLC regarding a 'Proposed placing of new ordinary shares' to raise capital for a transaction and debt repayment. It details the purpose of the capital raise, the involvement of financial advisors (Goldman Sachs, Morgan Stanley), and the regulatory conditions for the share issuance. This falls squarely under the definition of a 'Share Issue/Capital Change' (SHA) announcement, as it describes the company's plan to issue new shares to institutional investors.
2019-03-29 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.